Metabolically normal obeses subjects;Sujets obèses sans anomalies métaboliques

Revue Medicale de Liege

Volumn 64, Issue 3, 2009, Pages 148-157

  Esser, N ^a   Scheen, A J ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Metabolic syndrome; Metabolically obese normal weight; Obesity; Visceral adipose tissue

Indexed keywords

ADIPONECTIN; INSULIN; INTERLEUKIN 6; LIPID; TRIACYLGLYCEROL;

ADIPOSE TISSUE; BIOLOGICAL TRAIT; CARDIOVASCULAR RISK; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INTRAABDOMINAL FAT; METABOLICALLY NORMAL OBESE; OBESITY; PATHOPHYSIOLOGY; PHENOTYPE; PREVALENCE; PROGNOSIS; REVIEW;

HUMANS; OBESITY; PREVALENCE; PROGNOSIS;

EID: 63849243056     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Scheen AJ.-Le syndrome métabolique : physiopatho-logie et traitement. In : Athérosclérose Athérothrombose (Eds : Kulbertus H., Van Mieghem W.), Transmed Medical Communications, Lubbeek, Belgium, 2006, 161-190.
2. Rorive M, Letiexhe MR, Scheen AJ, Ziegler O.-Obésité et diabète de type 2. Rev Med Liège, 2005, 60, 374-382.
3. Beck E, Scheen AJ.-Sujets 〈métaboliquement obèses〉 sans excès de poids : un phénotype interpellant. Rev Med Liège, 2009, 64, sous presse
4. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S.-The metabolically obese, normal-weight individual revisited. Diabetes, 1998, 47, 699-713.
5. Brochu M, Tchernof A, Dionne IJ, et al.-What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J Clin Endocrinol Metab, 2001, 86, 1020-1025.
6. Sims EA.-Are there persons who are obese, but metabolically healthy ? Metabolism, 2001, 50, 1499-1504.
7. Karelis AD, St-Pierre DH, Conus F, et al.-Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab, 2004, 89, 2569-2575.
8. Karelis AD.-Metabolically healthy but obese individuals. Lancet, 2008, 372, 1281-1283.
9. Wildman RP, Muntner P, Reynolds K, et al.-The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering. Prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med, 2008, 168, 1617-1624.
10. Stefan N, Kantartzis K, Machann J, et al.-Identification and characterization of metabolically benign obesity in humans. Arch Intern Med, 2008, 168, 1609-1616.
11. Kelishadi R, Cook SR, Esmaeil M, et al.-Metabolically obese normal weight and phenotypically obese metabolically normal youths: the CASPIAN study. J Am Diet Assoc, 2008, 108, 82-90
12. Scheen AJ.-Evaluation de l'insulinosécrétion et de l'insulinosensibilité chez l'homme. Thérapie, 2007, 62, 311-318.
13. Park YW, Zhu S, Palaniappan L, et al.-The metabolic syndrome : prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med, 2003, 163, 427-436.
14. Ford ES.-Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care, 2005, 28, 2745-2749.
15. Meigs JB, Wilson PWF, Fox CS, et al.-Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab, 2006, 91, 2906-2912.
16. Marchesini G, Melchionda N, Apolone G, et al.-The metabolic syndrome in treatment-seeking obese persons. Metabolism, 2004, 53, 435-440.
17. Iacobellis G, Ribaudo MC, Zappaterreno A, et al.-Prevalence of uncomplicated obesity in an Italian obese population. Obes Res, 2005, 13, 1116-1122.
18. Aguilar-Salinas CA, Garcia Garcia E, Robles L, et al.-High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J Clin Endocrinol Metab, 2008, 93, 4075-4079.
19. Guerre-Millo M.-Adiponectin : an update. Diabetes Metab, 2008, 34, 12-18.
20. Bonora E, Kiechl J, Oberhollenzer F, et al.-Prevalence of insulin resistance in metabolic disorders: the Brun-neck study. Diabetes, 1998, 47, 1643-1650.
21. Reaven G.-All obese are not created equal: insulin resistance is the major determinant of cardiovascular disease in overweight/obese individuals. Diab Vasc Dis Res, 2005, 2, 105-112.
22. McLaughlin T, Allison G, Abbasi F, et al.-Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism, 2004, 53, 495-499.
23. Ferrannini E, Natali A, Bell P, et al.-Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest, 1997, 100, 1166-1173.
24. Magis D, Geronooz I, Scheen AJ.-Tabagisme, insuli-norésistance et diabète de type 2. Rev Med Liège, 2002, 57, 575-581.
25. Magis D, Jandrain BJ, Scheen AJ.-Alcool, sensibilité a l'insuline et diabete sucre. Rev Med Liege, 2003, 58, 501-507.
26. Hayes L, Pearce MS, Unwin NC.-Lifecourse predictors of normal metabolic parameters in overweight and obese adults. Int J Obes (Lond), 2006, 30, 970-976.
27. Colombo O, Villani S, Pinelli G, et al.-To treat or not to treat : comparison of different criteria used to determine whether weight loss is to be recommended. Nutr J, 2008, 7, 5.
28. Janssen I, Katzmarzyk PT, Ross R.-Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr, 2004, 79, 379-384 29. Buemann B, Astrup A, Pedersen O, et al.-Possible role of adiponectin and insulin sensitivity in mediating the favorable effects of lower body fat mass on blood lipids. J Clin Endocrinol Metab, 2006, 91, 1698-1704
29. Snijder MB, Dekker JM, Visser M, et al.-Larger thigh and hip circumferences are associated with better glucose tolerance : the Hoorn Study. Obes Res, 2003, 11, 104-111.
30. Freedland ES.-Role of a critical adipose tissue threshold (CVATT) in metabolic syndrome: implication of controlling dietary carbohydrates: a review. Nutr Metab (Lond), 2004, 1, 12.
31. Succurro E, Marini MA, Frontoni S, et al.-Insulin secretion in metabolically obese, but normal weight, and in metabolically healthy but obese individuals. Obesity, 2008 16, 1881-1886.
32. Karelis AD, Faraj M, Bastard JP, et al.-The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab, 2005, 90, 4145-4150.
33. Shin MJ, Hyun YJ, Kim OY, et al.-Weight loss effect on inflammation and LDL oxidation in metabolically healthy but obese (MHO) individuals: low inflammation and LDL oxidation in MHO women. Int J Obes Relat Metab Disord, 2006, 30, 1529-1534.
34. Karelis AD, Messier V, Brochu M, Rabasa-Lhoret R.-Metabolically healthy but obese women: effect of an energy-restricted diet. Diabetologia, 2008, 51, 1752-1754.
35. Wajchenberg BL.-Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev, 2000, 21, 697-738.
36. Després JP.-Is visceral obesity the cause of the metabolic syndrome? Ann Med, 2006, 38, 52-63.
37. Snijder MB, Zimmer PZ, Visser M, et al.-Independent and opposite associations of waist and hip circumferences with diabetes, hypertension and dyslipidemia: the AusDiab Study. Int J Obes Relat Metab Disord, 2004, 28, 402-409.
38. Boorsma W, Snijder MB, Nijpels G, et al.-Body composition, insulin sensitivity, and cardiovascular disease profile in healthy Europeans. Obesity, 2008, Oct 16 [Epub ahead of print].
39. Abbasi F, Chu JW, Malendola C, et al.-Discrimination between obesity and insulin resistance in the relationship with adiponectin. Diabetes, 2004, 53, 585-590.
40. Landsberg L.-Body fat distribution and cardiovascular risk. A tale of 2 sites. Arch Intern Med, 2008, 168, 1607-1608.
41. The DECODE Study Group.-Does the constellation of risk factors with and without abdominal adiposity associate with different cardiovascular mortality risk? Int J Obes Relat Metab Disord, 2008, 32, 757-762.
42. Marini MA, Succurro E, Frontoni S, et al.-Metabolically healthy but obese women have an intermediate cardiovascular risk profile between healthy nonobese women and obese insulin-resistant women. Diabetes Care, 2007, 30, 2145-2147.
43. Scheen AJ.-The future of obesity: new drugs versus lifestyle interventions ? (Editorial). Exp Opin Invest Drugs, 2008, 17, 263-267.
44. Scheen AJ, Paquot N.-Effets bénéfiques de l'activité physique sur les facteurs de risque cardio-vasculaire. Rev Med Liege, 2001, 56, 239-243.
45. Messier V, Malita FM, Rabasa-Lhoret R, et al.-Association of cardiorespiratory fitness with insulin sensitivity in overweight and obese postmenopausal women: a Montreal Ottawa New Emerging Team study. Metabolism, 2008, 57, 1293-1298.